The Super Bowl logo has become more of a talking point among NFL fans over the last few seasons. Part of the reason for that is a conspiracy theory that the colors of the Super Bowl logo determine ...

The deal comes at a time when the Anglo-Swedish pharma company is facing a string of investigations in the country, ...

OpenAI’s big rebranding effort brings a new logo and a new typeface, OpenAI sans. OpenAI’s big rebranding effort brings a new logo and a new typeface, OpenAI sans. Emma Roth is a news writer ...

where the drug is approved under the brand name Evrenzo. Today’s acquisition sees AstraZeneca pay FibroGen an enterprise value of $85 million along with $75 million of net cash that FibroGen ...

The UK-headquartered group has agreed to buy the Chinese subsidiary of FibroGen for around $160 million, claiming ownership of Evrenzo (roxadustat), FibroGen's treatment for anaemia associated ...

Last year, AZ recorded $336 million in revenue from the drug, sold as Evrenzo in China, a 22% increase despite generic competition. 3. FDA approves Ono's rare tumor drug from $2.4B Deciphera ...

But the visual representation of this industry disruptor is not a swirling black-void logo à la OpenAI, or even a robot. Instead, it’s a friendly blue whale. This diverges from branding trends ...

The FibroGen-AstraZeneca drug, marketed as Evrenzo, is currently approved in China, Europe, Japan, and over 40 other countries for the treatment of anemia in patients with chronic kidney disease.

Astellas' oral HIF-PH inhibitor Evrenzo has become the first drug in the class to be recommended for routine NHS use as a treatment for anaemia in chronic kidney disease (CKD), ahead of rivals ...

On Monday, three logos were revealed to the public, one for each potential nickname, but NHL fans weren't particularly impressed by the latest round of options. Much of the criticism was focused ...

Company to continue to advance its oncology pipeline, with the initiation of the Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) in 2Q 2025 Preliminary ...